Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
The approval is for Cytomegalovirus, a type of Herpes virus
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
The clinical trial, to be conducted in two phases, will evaluate the safety and efficacy of Mesocel for the treatment of patients with moderate to severe Covid-19
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Subscribe To Our Newsletter & Stay Updated
